Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00811889 · ClinicalTrials.gov registry record · Phase 2

Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease

A Phase 2 study of Type 2 Diabetes and Chronic Kidney Disease, sponsored by Biogen.

Completed
Registry status
Phase 2
Development phase
227
Enrollment target
20
Study locations

NCT00811889 is a Phase 2 study of Type 2 Diabetes and Chronic Kidney Disease that has completed, run by Biogen. The registered enrollment target is 227 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00811889, a Phase 2 study of Type 2 Diabetes and Chronic Kidney Disease, has completed, sponsored by Biogen.

COMPLETED
Registry status
Phase 2
Development phase
227 participants
Enrollment target
20
Study locations

Study Summary

This study assesses the effects of bardoxolone methyl (RTA 402) in patients with type 2 diabetes and chronic kidney disease.

Conditions Studied

Type 2 Diabetes Chronic Kidney Disease Diabetic Nephropathy

Interventions

  • OTHER Placebo
  • DRUG Bardoxolone Methyl (RTA 402)

Study Locations (20)

California

  • - Chula Vista
  • - La Mesa
  • - Mission Viejo
  • - Orange
  • - Riverside
  • - San Dimas

Florida

  • - Brandon
  • - Miami
  • - Pembroke Pines
  • - Port Charlotte
  • - West Palm Beach

Alabama

  • - Birmingham
  • - Montgomery

Illinois

  • - Chicago
  • - Peoria

Connecticut

  • - Middlebury

District of Columbia

  • - Washington D.C.

Georgia

  • - Marietta

Louisiana

  • - Baton Rouge

Trial Details

FieldValue
Enrollment Target 227 participants
Start Date 2009-04-30
Est. Completion 2010-12-31
Phase Phase 2

Sponsor

Biogen

334 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00811889

The ClinicalTrials.gov registry entry for NCT00811889 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 227 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (79% lower). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00811889 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT00811889 about?

NCT00811889 is a clinical study titled "Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease". This study assesses the effects of bardoxolone methyl (RTA 402) in patients with type 2 diabetes and chronic kidney disease.

What is the current status of trial NCT00811889?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 227 participants. The study started on 2009-04-30. Estimated completion is 2010-12-31.

What conditions does trial NCT00811889 study?

This clinical trial studies the following conditions: Type 2 Diabetes, Chronic Kidney Disease, Diabetic Nephropathy.

What interventions are being tested in trial NCT00811889?

The interventions under investigation include: Placebo (OTHER), Bardoxolone Methyl (RTA 402) (DRUG).

Who is sponsoring clinical trial NCT00811889?

This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00811889 being conducted?

This trial has 20 study locations across Alabama, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes

All registered trials for this condition

Chronic Kidney Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.